PDCD1 and breast cancer: Although it is still under investigation, the ICHs which target the programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway or cytotoxic T-lymphocyte-associated protein4 (CTLA-4) [141] have been challenged and shown great promise in advanced BC in some patients.